Molecular Weight:   | 238.06 |
Volume:   | 247.606 |
LogP:   | 3.846 |
LogD:   | 3.02 |
LogS:   | -3.688 |
# Rotatable Bonds:   | 1 |
TPSA:   | 50.44 |
# H-Bond Aceptor:   | 3 |
# H-Bond Donor:   | 1 |
# Rings:   | 3 |
# Heavy Atoms:   | 3 |
QED Drug-Likeness Score:   | 0.708 |
Synthetic Accessibility Score:   | 1.931 |
Fsp3:   | 0.0 |
Lipinski Rule-of-5:   | Accepted |
Pfizer Rule:   | Rejected |
GSK Rule:   | Accepted |
BMS Rule:   | 0 |
Golden Triangle Rule:   | Accepted |
Chelating Alert:   | 0 |
PAINS Alert:   | 0 |
Caco-2 Permeability:   | -4.803 |
MDCK Permeability:   | 1.440442429156974e-05 |
Pgp-inhibitor:   | 0.096 |
Pgp-substrate:   | 0.405 |
Human Intestinal Absorption (HIA):   | 0.007 |
20% Bioavailability (F20%):   | 0.989 |
30% Bioavailability (F30%):   | 0.999 |
Blood-Brain-Barrier Penetration (BBB):   | 0.09 |
Plasma Protein Binding (PPB):   | 97.67887878417969% |
Volume Distribution (VD):   | 0.468 |
Pgp-substrate:   | 2.5304181575775146% |
CYP1A2-inhibitor:   | 0.99 |
CYP1A2-substrate:   | 0.476 |
CYP2C19-inhibitor:   | 0.837 |
CYP2C19-substrate:   | 0.068 |
CYP2C9-inhibitor:   | 0.704 |
CYP2C9-substrate:   | 0.914 |
CYP2D6-inhibitor:   | 0.495 |
CYP2D6-substrate:   | 0.762 |
CYP3A4-inhibitor:   | 0.304 |
CYP3A4-substrate:   | 0.166 |
Clearance (CL):   | 3.18 |
Half-life (T1/2):   | 0.444 |
hERG Blockers:   | 0.037 |
Human Hepatotoxicity (H-HT):   | 0.056 |
Drug-inuced Liver Injury (DILI):   | 0.861 |
AMES Toxicity:   | 0.695 |
Rat Oral Acute Toxicity:   | 0.176 |
Maximum Recommended Daily Dose:   | 0.048 |
Skin Sensitization:   | 0.772 |
Carcinogencity:   | 0.654 |
Eye Corrosion:   | 0.023 |
Eye Irritation:   | 0.966 |
Respiratory Toxicity:   | 0.498 |
Natural Product ID:   | NPC197425 |
Common Name*:   | 5-Hydroxyflavone |
IUPAC Name:   | 5-hydroxy-2-phenylchromen-4-one |
Synonyms:   | NSC-26745 |
Standard InCHIKey:   | IYBLVRRCNVHZQJ-UHFFFAOYSA-N |
Standard InCHI:   | InChI=1S/C15H10O3/c16-11-7-4-8-13-15(11)12(17)9-14(18-13)10-5-2-1-3-6-10/h1-9,16H |
SMILES:   | Oc1cccc2c1c(=O)cc(o2)c1ccccc1 |
Synthetic Gene Cluster:   | n.a. |
ChEMBL Identifier:   | CHEMBL16807 |
PubChem CID:   |
68112 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO22583 | Daedaleopsis confragosa | Species | Coriolaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[11014261] |
NPO18557 | Epicoccum nigrum | Species | Didymellaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[17711348] |
NPO18557 | Epicoccum nigrum | Species | Didymellaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[19919067] |
NPO18557 | Epicoccum nigrum | Species | Didymellaceae | Eukaryota | n.a. | The fungus is isolated from the leaves of L. rhodostegia, collected in June 2007 at Nanning, Guangxi Province, China | 2007-JUN |
PMID[20550196] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[23501116] |
NPO18557 | Epicoccum nigrum | Species | Didymellaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[24328302] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[24471493] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | Flowers | n.a. | n.a. |
PMID[28116906] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | Flower | n.a. | n.a. | Database[FooDB] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | Plant | n.a. | n.a. | Database[FooDB] |
NPO2688 | Pericarpium pyri | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[HerDing] |
NPO24045 | Lespedeza homoloba | Species | Fabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO24284 | Hypoestes serpens | Species | Acanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO2688 | Pericarpium pyri | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[TCMID] |
NPO24045 | Lespedeza homoloba | Species | Fabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO18557 | Epicoccum nigrum | Species | Didymellaceae | Eukaryota | n.a. | n.a. | n.a. | Database[Title] |
NPO24045 | Lespedeza homoloba | Species | Fabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO24173 | Plutella xylostella | Species | Plutellidae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO24284 | Hypoestes serpens | Species | Acanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO22583 | Daedaleopsis confragosa | Species | Coriolaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO24329 | Primula farinosa | Species | Primulaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO20617 | Tilletia laevis | Species | Tilletiaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO24216 | Lolium perenne | Species | Poaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO23916 | Anthocleista grandiflora | Species | Gentianaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO23957 | Helleborus caucasicus | Species | Ranunculaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO17647 | Schkuhria multiflora | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO16234 | Orgyia australis postica | Species | Lymantriidae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO18557 | Epicoccum nigrum | Species | Didymellaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO15440 | Chamaemelum nobile | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT581 | Individual Protein | Cyclooxygenase-2 | Mus musculus | Inhibition | = | 45.0 | % | PMID[514092] |
NPT1315 | Individual Protein | Adenosine A1 receptor | Rattus norvegicus | pKi(uM) | = | -0.34 | n.a. | PMID[514094] |
NPT1316 | Individual Protein | Adenosine A2a receptor | Rattus norvegicus | pKi(uM) | = | -0.79 | n.a. | PMID[514095] |
NPT1315 | Individual Protein | Adenosine A1 receptor | Rattus norvegicus | Ki | = | 2170.0 | nM | PMID[514096] |
NPT1316 | Individual Protein | Adenosine A2a receptor | Rattus norvegicus | Ki | = | 6200.0 | nM | PMID[514096] |
NPT218 | Individual Protein | Adenosine A3 receptor | Homo sapiens | Displacement | = | 47.0 | % | PMID[514096] |
NPT91 | Cell Line | KB | Homo sapiens | ED50 | = | 20.0 | ug ml-1 | PMID[514101] |
NPT1044 | Individual Protein | DNA topoisomerase II alpha | Homo sapiens | Activity | < | 50.0 | % | PMID[514102] |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | IC50 | = | 300.0 | nM | PMID[514103] |
NPT249 | Individual Protein | Glucocorticoid receptor | Homo sapiens | EC150 | = | 6.0 | uM | PMID[514103] |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | EC150 | = | 6.0 | uM | PMID[514103] |
NPT1338 | Individual Protein | Sialidase 2 | Homo sapiens | IC50 | > | 1000000.0 | nM | PMID[514105] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 15848.9 | nM | PMID[514107] |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | Potency | = | 6309.6 | nM | PMID[514108] |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | Potency | = | 19952.6 | nM | PMID[514107] |
NPT61 | Individual Protein | Beta-glucocerebrosidase | Homo sapiens | Potency | n.a. | 11220.2 | nM | PMID[514107] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 2310.9 | nM | PMID[514111] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 35481.3 | nM | PMID[514111] |
NPT208 | Individual Protein | Cytochrome P450 1A2 | Homo sapiens | IC50 | = | 310.0 | nM | PMID[514113] |
NPT1603 | Individual Protein | Cytochrome P450 1A1 | Homo sapiens | IC50 | = | 4030.0 | nM | PMID[514113] |
NPT160 | Individual Protein | TAR DNA-binding protein 43 | Homo sapiens | Potency | n.a. | 89125.1 | nM | PMID[514111] |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | IC50 | = | 831.76 | nM | PMID[514114] |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | IC50 | = | 840.0 | nM | PMID[514114] |
NPT11 | Individual Protein | Guanine nucleotide-binding protein G(s), subunit alpha | Homo sapiens | Potency | n.a. | 31622.8 | nM | PMID[514111] |
NPT65 | Cell Line | HepG2 | Homo sapiens | Activity | = | 88.8 | % | PMID[514117] |
NPT83 | Cell Line | MCF7 | Homo sapiens | Activity | = | 28.6 | % | PMID[514117] |
NPT111 | Cell Line | K562 | Homo sapiens | Activity | = | 26.7 | % | PMID[514117] |
NPT1604 | Individual Protein | Cytochrome P450 1B1 | Homo sapiens | IC50 | = | 210.0 | nM | PMID[514119] |
NPT2266 | Individual Protein | Fructose-1,6-bisphosphatase | Homo sapiens | Inhibition | < | 20.0 | % | PMID[514121] |
NPT711 | Individual Protein | Aldose reductase | Bos taurus | Inhibition | = | 0.0 | % | PMID[514091] |
NPT805 | Protein Complex | GABA-A receptor; anion channel | Rattus norvegicus | Ki | = | 1900.0 | nM | PMID[514093] |
NPT805 | Protein Complex | GABA-A receptor; anion channel | Rattus norvegicus | GABA ratio | = | 1.03 | n.a. | PMID[514093] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Protection | = | 58.0 | % | PMID[514097] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 65900.0 | nM | PMID[514098] |
NPT2 | Others | Unspecified | Inhibition | = | 17.0 | % | PMID[514099] | |
NPT2 | Others | Unspecified | Activity | = | 14.6 | % | PMID[514100] | |
NPT2 | Others | Unspecified | Activity | = | 95.7 | % | PMID[514100] | |
NPT2 | Others | Unspecified | Activity | = | 98.9 | % | PMID[514100] | |
NPT2 | Others | Unspecified | IC50 | = | 425.0 | nM | PMID[514100] | |
NPT35 | Others | n.a. | Activity | = | 11.6 | mg/L | PMID[514104] | |
NPT2 | Others | Unspecified | IC50 | > | 1000000.0 | nM | PMID[514105] | |
NPT566 | Organism | Salmonella typhimurium | Salmonella enterica subsp. enterica serovar Typhimurium | pID50 | = | 5.357 | n.a. | PMID[514106] |
NPT2 | Others | Unspecified | Potency | = | 316.2 | nM | PMID[514107] | |
NPT93 | Individual Protein | Survival motor neuron protein | Homo sapiens | Potency | = | 31622.8 | nM | PMID[514107] |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 39810.7 | nM | PMID[514107] |
NPT792 | Individual Protein | Arachidonate 15-lipoxygenase | Homo sapiens | Potency | = | 19952.6 | nM | PMID[514107] |
NPT197 | Protein-Protein Interaction | Menin/Histone-lysine N-methyltransferase MLL | Homo sapiens | Potency | = | 39810.7 | nM | PMID[514107] |
NPT2 | Others | Unspecified | Potency | = | 15848.9 | nM | PMID[514108] | |
NPT2 | Others | Unspecified | Inhibition | = | 115.9 | % | PMID[514110] | |
NPT698 | Individual Protein | Regulator of G-protein signaling 4 | Homo sapiens | Potency | n.a. | 8436.8 | nM | PMID[514108] |
NPT8 | Individual Protein | DNA polymerase iota | Homo sapiens | Potency | n.a. | 89125.1 | nM | PMID[514111] |
NPT1 | Others | Radical scavenging activity | Inhibition | = | 0.6 | % | PMID[514112] | |
NPT27 | Others | Unspecified | Selectivity ratio | = | 10.0 | n.a. | PMID[514113] | |
NPT2 | Others | Unspecified | Inhibition | < | 40.0 | % | PMID[514115] | |
NPT2 | Others | Unspecified | IC50 | = | 96000.0 | nM | PMID[514115] | |
NPT2 | Others | Unspecified | Inhibition | = | 30.1 | % | PMID[514115] | |
NPT27 | Others | Unspecified | Activity | > | 98.0 | % | PMID[514115] | |
NPT2 | Others | Unspecified | Potency | n.a. | 15848.9 | nM | PMID[514108] | |
NPT2 | Others | Unspecified | Potency | n.a. | 11220.2 | nM | PMID[514107] | |
NPT2 | Others | Unspecified | Potency | n.a. | 1122.0 | nM | PMID[514107] | |
NPT2 | Others | Unspecified | Potency | n.a. | 14125.4 | nM | PMID[514108] | |
NPT2 | Others | Unspecified | Kapp | = | 313.0 | /M | PMID[514117] | |
NPT2 | Others | Unspecified | Kapp | = | 229.0 | /M | PMID[514117] | |
NPT21750 | LIPID | Lipid bilayer | n.a. | T | = | 32.3 | degrees C | PMID[514117] |
NPT21750 | LIPID | Lipid bilayer | n.a. | T | = | 32.0 | degrees C | PMID[514117] |
NPT21750 | LIPID | Lipid bilayer | n.a. | T | = | 30.3 | degrees C | PMID[514117] |
NPT21750 | LIPID | Lipid bilayer | n.a. | Tm | = | 41.1 | degrees C | PMID[514117] |
NPT21750 | LIPID | Lipid bilayer | n.a. | Tm | = | 40.7 | degrees C | PMID[514117] |
NPT21750 | LIPID | Lipid bilayer | n.a. | Tm | = | 40.6 | degrees C | PMID[514117] |
NPT21750 | LIPID | Lipid bilayer | n.a. | Tm | = | 39.6 | degrees C | PMID[514117] |
NPT1 | Others | Radical scavenging activity | IC50 | = | 23.8 | ug.mL-1 | PMID[514117] | |
NPT2 | Others | Unspecified | Potency | n.a. | 5623.4 | nM | PMID[514107] | |
NPT2 | Others | Unspecified | Potency | n.a. | 5623.4 | nM | PMID[514111] | |
NPT471 | Organism | Trypanosoma brucei brucei | Trypanosoma brucei brucei | IC50 | < | 30000.0 | nM | PMID[514120] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | IC50 | > | 20000.0 | nM | PMID[514122] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | IC50 | > | 19952.62 | nM | PMID[514122] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC197425 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9919 | High Similarity | NPC39753 |
0.9919 | High Similarity | NPC115998 |
0.9839 | High Similarity | NPC137264 |
0.976 | High Similarity | NPC113006 |
0.9683 | High Similarity | NPC128216 |
0.9606 | High Similarity | NPC50898 |
0.9606 | High Similarity | NPC78540 |
0.9606 | High Similarity | NPC274121 |
0.9606 | High Similarity | NPC57601 |
0.9606 | High Similarity | NPC213216 |
0.9531 | High Similarity | NPC172262 |
0.9531 | High Similarity | NPC248872 |
0.952 | High Similarity | NPC187907 |
0.9431 | High Similarity | NPC193805 |
0.9385 | High Similarity | NPC187432 |
0.9385 | High Similarity | NPC256042 |
0.9385 | High Similarity | NPC29353 |
0.9385 | High Similarity | NPC234133 |
0.9385 | High Similarity | NPC124784 |
0.9385 | High Similarity | NPC47815 |
0.9385 | High Similarity | NPC473887 |
0.9385 | High Similarity | NPC194281 |
0.9385 | High Similarity | NPC116775 |
0.9385 | High Similarity | NPC216361 |
0.9385 | High Similarity | NPC281917 |
0.9385 | High Similarity | NPC13408 |
0.9385 | High Similarity | NPC231772 |
0.9385 | High Similarity | NPC127447 |
0.936 | High Similarity | NPC22783 |
0.936 | High Similarity | NPC41721 |
0.9313 | High Similarity | NPC250266 |
0.9313 | High Similarity | NPC266597 |
0.9313 | High Similarity | NPC299379 |
0.9313 | High Similarity | NPC228661 |
0.9308 | High Similarity | NPC239495 |
0.9308 | High Similarity | NPC9985 |
0.9242 | High Similarity | NPC201395 |
0.9219 | High Similarity | NPC5515 |
0.9219 | High Similarity | NPC270369 |
0.9173 | High Similarity | NPC78913 |
0.9173 | High Similarity | NPC18260 |
0.9173 | High Similarity | NPC241838 |
0.9173 | High Similarity | NPC143799 |
0.9173 | High Similarity | NPC55018 |
0.9173 | High Similarity | NPC301217 |
0.9173 | High Similarity | NPC152042 |
0.9173 | High Similarity | NPC303633 |
0.9173 | High Similarity | NPC96565 |
0.9173 | High Similarity | NPC220062 |
0.9173 | High Similarity | NPC216978 |
0.9167 | High Similarity | NPC13768 |
0.9167 | High Similarity | NPC84585 |
0.9167 | High Similarity | NPC243083 |
0.9167 | High Similarity | NPC476480 |
0.9167 | High Similarity | NPC79943 |
0.9167 | High Similarity | NPC287246 |
0.9167 | High Similarity | NPC12296 |
0.9167 | High Similarity | NPC290291 |
0.9167 | High Similarity | NPC275055 |
0.9167 | High Similarity | NPC32441 |
0.9167 | High Similarity | NPC295261 |
0.9167 | High Similarity | NPC296490 |
0.9167 | High Similarity | NPC107586 |
0.9147 | High Similarity | NPC31872 |
0.9147 | High Similarity | NPC473584 |
0.9147 | High Similarity | NPC475589 |
0.9104 | High Similarity | NPC103904 |
0.9104 | High Similarity | NPC305355 |
0.9104 | High Similarity | NPC146679 |
0.9104 | High Similarity | NPC281207 |
0.9104 | High Similarity | NPC230285 |
0.9104 | High Similarity | NPC59951 |
0.9104 | High Similarity | NPC269652 |
0.9104 | High Similarity | NPC475680 |
0.9104 | High Similarity | NPC241100 |
0.9104 | High Similarity | NPC270883 |
0.9104 | High Similarity | NPC103342 |
0.9104 | High Similarity | NPC172986 |
0.9104 | High Similarity | NPC159275 |
0.9104 | High Similarity | NPC184536 |
0.9104 | High Similarity | NPC261227 |
0.9098 | High Similarity | NPC99333 |
0.9098 | High Similarity | NPC188947 |
0.9098 | High Similarity | NPC329225 |
0.9098 | High Similarity | NPC280284 |
0.9098 | High Similarity | NPC18457 |
0.9098 | High Similarity | NPC472460 |
0.9098 | High Similarity | NPC118813 |
0.9098 | High Similarity | NPC147686 |
0.9091 | High Similarity | NPC240593 |
0.9077 | High Similarity | NPC25937 |
0.9077 | High Similarity | NPC10971 |
0.9037 | High Similarity | NPC156590 |
0.9037 | High Similarity | NPC90582 |
0.9037 | High Similarity | NPC147688 |
0.9037 | High Similarity | NPC282300 |
0.9037 | High Similarity | NPC205006 |
0.9037 | High Similarity | NPC14871 |
0.9037 | High Similarity | NPC118840 |
0.9037 | High Similarity | NPC110969 |
0.9037 | High Similarity | NPC262094 |
0.9037 | High Similarity | NPC136840 |
0.9037 | High Similarity | NPC64908 |
0.903 | High Similarity | NPC265871 |
0.903 | High Similarity | NPC261234 |
0.903 | High Similarity | NPC217186 |
0.903 | High Similarity | NPC225153 |
0.903 | High Similarity | NPC274784 |
0.903 | High Similarity | NPC20709 |
0.903 | High Similarity | NPC150648 |
0.903 | High Similarity | NPC222342 |
0.903 | High Similarity | NPC316480 |
0.903 | High Similarity | NPC329203 |
0.903 | High Similarity | NPC310135 |
0.903 | High Similarity | NPC53181 |
0.9023 | High Similarity | NPC254841 |
0.9023 | High Similarity | NPC160972 |
0.9023 | High Similarity | NPC188879 |
0.9015 | High Similarity | NPC151113 |
0.9015 | High Similarity | NPC39426 |
0.9015 | High Similarity | NPC234560 |
0.9008 | High Similarity | NPC223457 |
0.9008 | High Similarity | NPC108113 |
0.9008 | High Similarity | NPC93756 |
0.9 | High Similarity | NPC308037 |
0.9 | High Similarity | NPC64359 |
0.9 | High Similarity | NPC284424 |
0.9 | High Similarity | NPC313618 |
0.9 | High Similarity | NPC475009 |
0.9 | High Similarity | NPC278556 |
0.9 | High Similarity | NPC186097 |
0.9 | High Similarity | NPC475008 |
0.8992 | High Similarity | NPC228184 |
0.8992 | High Similarity | NPC12694 |
0.8971 | High Similarity | NPC11561 |
0.8971 | High Similarity | NPC78803 |
0.8971 | High Similarity | NPC214236 |
0.8971 | High Similarity | NPC217083 |
0.8971 | High Similarity | NPC293852 |
0.8971 | High Similarity | NPC200694 |
0.8971 | High Similarity | NPC226636 |
0.8971 | High Similarity | NPC62840 |
0.8971 | High Similarity | NPC473042 |
0.8971 | High Similarity | NPC1534 |
0.8971 | High Similarity | NPC59739 |
0.8971 | High Similarity | NPC299080 |
0.8963 | High Similarity | NPC235239 |
0.8963 | High Similarity | NPC110228 |
0.8963 | High Similarity | NPC284550 |
0.8963 | High Similarity | NPC76445 |
0.8963 | High Similarity | NPC145673 |
0.8963 | High Similarity | NPC188243 |
0.8963 | High Similarity | NPC69769 |
0.8963 | High Similarity | NPC150522 |
0.8963 | High Similarity | NPC6407 |
0.8963 | High Similarity | NPC129853 |
0.8955 | High Similarity | NPC124269 |
0.8955 | High Similarity | NPC276905 |
0.8947 | High Similarity | NPC235428 |
0.8947 | High Similarity | NPC87545 |
0.8939 | High Similarity | NPC125920 |
0.8931 | High Similarity | NPC257756 |
0.8931 | High Similarity | NPC212631 |
0.8931 | High Similarity | NPC129132 |
0.8931 | High Similarity | NPC101294 |
0.8931 | High Similarity | NPC473655 |
0.8931 | High Similarity | NPC87231 |
0.8931 | High Similarity | NPC205468 |
0.8915 | High Similarity | NPC60558 |
0.8905 | High Similarity | NPC24821 |
0.8905 | High Similarity | NPC11700 |
0.8905 | High Similarity | NPC293053 |
0.8905 | High Similarity | NPC470216 |
0.8905 | High Similarity | NPC279121 |
0.8905 | High Similarity | NPC9117 |
0.8905 | High Similarity | NPC219915 |
0.8905 | High Similarity | NPC212932 |
0.8905 | High Similarity | NPC38219 |
0.8905 | High Similarity | NPC190637 |
0.8897 | High Similarity | NPC324386 |
0.8897 | High Similarity | NPC3188 |
0.8897 | High Similarity | NPC312391 |
0.8897 | High Similarity | NPC213322 |
0.8897 | High Similarity | NPC103362 |
0.8897 | High Similarity | NPC4743 |
0.8889 | High Similarity | NPC140890 |
0.8889 | High Similarity | NPC93730 |
0.8881 | High Similarity | NPC294409 |
0.8881 | High Similarity | NPC116632 |
0.8881 | High Similarity | NPC303644 |
0.8881 | High Similarity | NPC162680 |
0.8881 | High Similarity | NPC181124 |
0.8881 | High Similarity | NPC7013 |
0.8881 | High Similarity | NPC212767 |
0.8881 | High Similarity | NPC209560 |
0.8881 | High Similarity | NPC332594 |
0.8872 | High Similarity | NPC60667 |
0.8872 | High Similarity | NPC242712 |
0.8864 | High Similarity | NPC28753 |
0.8864 | High Similarity | NPC337373 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC197425 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9167 | High Similarity | NPD1550 | Clinical (unspecified phase) |
0.9167 | High Similarity | NPD1552 | Clinical (unspecified phase) |
0.9098 | High Similarity | NPD1549 | Phase 2 |
0.9015 | High Similarity | NPD1510 | Phase 2 |
0.9 | High Similarity | NPD1240 | Approved |
0.8905 | High Similarity | NPD1511 | Approved |
0.8864 | High Similarity | NPD1607 | Approved |
0.8841 | High Similarity | NPD4378 | Clinical (unspecified phase) |
0.8806 | High Similarity | NPD1551 | Phase 2 |
0.8777 | High Similarity | NPD1512 | Approved |
0.875 | High Similarity | NPD1203 | Approved |
0.8705 | High Similarity | NPD7410 | Clinical (unspecified phase) |
0.8686 | High Similarity | NPD3750 | Approved |
0.8667 | High Similarity | NPD2796 | Approved |
0.8451 | Intermediate Similarity | NPD5403 | Approved |
0.844 | Intermediate Similarity | NPD5401 | Approved |
0.8438 | Intermediate Similarity | NPD1547 | Clinical (unspecified phase) |
0.8413 | Intermediate Similarity | NPD1548 | Phase 1 |
0.8372 | Intermediate Similarity | NPD9717 | Approved |
0.8356 | Intermediate Similarity | NPD2801 | Approved |
0.8321 | Intermediate Similarity | NPD3748 | Approved |
0.8295 | Intermediate Similarity | NPD422 | Phase 1 |
0.8288 | Intermediate Similarity | NPD1934 | Approved |
0.8286 | Intermediate Similarity | NPD1878 | Clinical (unspecified phase) |
0.8284 | Intermediate Similarity | NPD2313 | Discontinued |
0.8276 | Intermediate Similarity | NPD4380 | Phase 2 |
0.8273 | Intermediate Similarity | NPD970 | Clinical (unspecified phase) |
0.8239 | Intermediate Similarity | NPD6799 | Approved |
0.8231 | Intermediate Similarity | NPD2393 | Clinical (unspecified phase) |
0.8219 | Intermediate Similarity | NPD7411 | Suspended |
0.8188 | Intermediate Similarity | NPD4381 | Clinical (unspecified phase) |
0.8182 | Intermediate Similarity | NPD2797 | Approved |
0.8176 | Intermediate Similarity | NPD8443 | Clinical (unspecified phase) |
0.812 | Intermediate Similarity | NPD2798 | Approved |
0.8106 | Intermediate Similarity | NPD3225 | Approved |
0.8085 | Intermediate Similarity | NPD1243 | Approved |
0.8067 | Intermediate Similarity | NPD3749 | Approved |
0.8067 | Intermediate Similarity | NPD7075 | Discontinued |
0.8054 | Intermediate Similarity | NPD5402 | Approved |
0.8041 | Intermediate Similarity | NPD6801 | Discontinued |
0.8015 | Intermediate Similarity | NPD1610 | Phase 2 |
0.8015 | Intermediate Similarity | NPD3268 | Approved |
0.8015 | Intermediate Similarity | NPD6859 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD7768 | Phase 2 |
0.8 | Intermediate Similarity | NPD6832 | Phase 2 |
0.8 | Intermediate Similarity | NPD3882 | Suspended |
0.7987 | Intermediate Similarity | NPD7096 | Clinical (unspecified phase) |
0.7987 | Intermediate Similarity | NPD7819 | Suspended |
0.7969 | Intermediate Similarity | NPD9493 | Approved |
0.7958 | Intermediate Similarity | NPD2800 | Approved |
0.7943 | Intermediate Similarity | NPD2344 | Approved |
0.7933 | Intermediate Similarity | NPD3817 | Phase 2 |
0.7929 | Intermediate Similarity | NPD4308 | Phase 3 |
0.7917 | Intermediate Similarity | NPD643 | Clinical (unspecified phase) |
0.7905 | Intermediate Similarity | NPD6599 | Discontinued |
0.7879 | Intermediate Similarity | NPD1201 | Approved |
0.7872 | Intermediate Similarity | NPD6100 | Approved |
0.7872 | Intermediate Similarity | NPD6099 | Approved |
0.7832 | Intermediate Similarity | NPD7421 | Clinical (unspecified phase) |
0.7808 | Intermediate Similarity | NPD642 | Clinical (unspecified phase) |
0.7801 | Intermediate Similarity | NPD2799 | Discontinued |
0.7778 | Intermediate Similarity | NPD3267 | Approved |
0.7778 | Intermediate Similarity | NPD3266 | Approved |
0.7771 | Intermediate Similarity | NPD3818 | Discontinued |
0.777 | Intermediate Similarity | NPD943 | Approved |
0.7756 | Intermediate Similarity | NPD7852 | Clinical (unspecified phase) |
0.7756 | Intermediate Similarity | NPD6167 | Clinical (unspecified phase) |
0.7756 | Intermediate Similarity | NPD6166 | Phase 2 |
0.7756 | Intermediate Similarity | NPD6168 | Clinical (unspecified phase) |
0.7754 | Intermediate Similarity | NPD1296 | Phase 2 |
0.7754 | Intermediate Similarity | NPD411 | Approved |
0.7746 | Intermediate Similarity | NPD2935 | Discontinued |
0.7724 | Intermediate Similarity | NPD2309 | Approved |
0.7722 | Intermediate Similarity | NPD7804 | Clinical (unspecified phase) |
0.7722 | Intermediate Similarity | NPD7054 | Approved |
0.7718 | Intermediate Similarity | NPD3226 | Approved |
0.7714 | Intermediate Similarity | NPD1933 | Approved |
0.7714 | Intermediate Similarity | NPD447 | Suspended |
0.7703 | Intermediate Similarity | NPD920 | Approved |
0.7692 | Intermediate Similarity | NPD2346 | Discontinued |
0.7687 | Intermediate Similarity | NPD1608 | Approved |
0.7677 | Intermediate Similarity | NPD6959 | Discontinued |
0.7676 | Intermediate Similarity | NPD7033 | Discontinued |
0.7673 | Intermediate Similarity | NPD7472 | Approved |
0.766 | Intermediate Similarity | NPD6651 | Approved |
0.7655 | Intermediate Similarity | NPD6398 | Clinical (unspecified phase) |
0.7647 | Intermediate Similarity | NPD1470 | Approved |
0.7643 | Intermediate Similarity | NPD4307 | Phase 2 |
0.7625 | Intermediate Similarity | NPD6797 | Phase 2 |
0.7619 | Intermediate Similarity | NPD74 | Approved |
0.7619 | Intermediate Similarity | NPD9266 | Approved |
0.7609 | Intermediate Similarity | NPD1529 | Clinical (unspecified phase) |
0.7609 | Intermediate Similarity | NPD4908 | Phase 1 |
0.7597 | Intermediate Similarity | NPD1241 | Discontinued |
0.7591 | Intermediate Similarity | NPD1019 | Discontinued |
0.7589 | Intermediate Similarity | NPD1899 | Clinical (unspecified phase) |
0.7582 | Intermediate Similarity | NPD4288 | Approved |
0.7578 | Intermediate Similarity | NPD7251 | Discontinued |
0.7562 | Intermediate Similarity | NPD7074 | Phase 3 |
0.7556 | Intermediate Similarity | NPD1481 | Phase 2 |
0.7554 | Intermediate Similarity | NPD4625 | Phase 3 |
0.7552 | Intermediate Similarity | NPD1509 | Clinical (unspecified phase) |
0.754 | Intermediate Similarity | NPD9267 | Approved |
0.754 | Intermediate Similarity | NPD9264 | Approved |
0.754 | Intermediate Similarity | NPD9263 | Approved |
0.7536 | Intermediate Similarity | NPD1530 | Clinical (unspecified phase) |
0.7532 | Intermediate Similarity | NPD4868 | Clinical (unspecified phase) |
0.7531 | Intermediate Similarity | NPD4338 | Clinical (unspecified phase) |
0.7531 | Intermediate Similarity | NPD4419 | Clinical (unspecified phase) |
0.7531 | Intermediate Similarity | NPD7808 | Phase 3 |
0.75 | Intermediate Similarity | NPD4749 | Approved |
0.75 | Intermediate Similarity | NPD4907 | Clinical (unspecified phase) |
0.7481 | Intermediate Similarity | NPD1535 | Discovery |
0.7469 | Intermediate Similarity | NPD6559 | Discontinued |
0.7463 | Intermediate Similarity | NPD17 | Approved |
0.7444 | Intermediate Similarity | NPD9545 | Approved |
0.7424 | Intermediate Similarity | NPD405 | Clinical (unspecified phase) |
0.7407 | Intermediate Similarity | NPD5953 | Discontinued |
0.7405 | Intermediate Similarity | NPD6232 | Discontinued |
0.7403 | Intermediate Similarity | NPD1465 | Phase 2 |
0.7394 | Intermediate Similarity | NPD1612 | Clinical (unspecified phase) |
0.7394 | Intermediate Similarity | NPD1613 | Approved |
0.7391 | Intermediate Similarity | NPD7286 | Phase 2 |
0.7391 | Intermediate Similarity | NPD1164 | Approved |
0.7389 | Intermediate Similarity | NPD5494 | Approved |
0.7376 | Intermediate Similarity | NPD3764 | Approved |
0.7375 | Intermediate Similarity | NPD7473 | Discontinued |
0.7357 | Intermediate Similarity | NPD1008 | Clinical (unspecified phase) |
0.7347 | Intermediate Similarity | NPD2654 | Approved |
0.7333 | Intermediate Similarity | NPD2532 | Approved |
0.7333 | Intermediate Similarity | NPD2534 | Approved |
0.7333 | Intermediate Similarity | NPD2533 | Approved |
0.7329 | Intermediate Similarity | NPD5940 | Clinical (unspecified phase) |
0.7325 | Intermediate Similarity | NPD919 | Approved |
0.7323 | Intermediate Similarity | NPD968 | Approved |
0.7313 | Intermediate Similarity | NPD1894 | Discontinued |
0.7312 | Intermediate Similarity | NPD7784 | Clinical (unspecified phase) |
0.7297 | Intermediate Similarity | NPD4628 | Phase 3 |
0.7244 | Intermediate Similarity | NPD9697 | Approved |
0.7233 | Intermediate Similarity | NPD1247 | Approved |
0.7226 | Intermediate Similarity | NPD6844 | Discontinued |
0.7222 | Intermediate Similarity | NPD5123 | Clinical (unspecified phase) |
0.7222 | Intermediate Similarity | NPD9261 | Approved |
0.7222 | Intermediate Similarity | NPD5124 | Phase 1 |
0.7219 | Intermediate Similarity | NPD7004 | Clinical (unspecified phase) |
0.7219 | Intermediate Similarity | NPD4662 | Approved |
0.7219 | Intermediate Similarity | NPD4661 | Approved |
0.7211 | Intermediate Similarity | NPD2343 | Clinical (unspecified phase) |
0.7192 | Intermediate Similarity | NPD651 | Clinical (unspecified phase) |
0.7174 | Intermediate Similarity | NPD3972 | Approved |
0.7161 | Intermediate Similarity | NPD7615 | Clinical (unspecified phase) |
0.7152 | Intermediate Similarity | NPD7390 | Discontinued |
0.7143 | Intermediate Similarity | NPD3926 | Phase 2 |
0.7143 | Intermediate Similarity | NPD5808 | Clinical (unspecified phase) |
0.7143 | Intermediate Similarity | NPD9281 | Approved |
0.7134 | Intermediate Similarity | NPD2296 | Approved |
0.7134 | Intermediate Similarity | NPD1729 | Discontinued |
0.7133 | Intermediate Similarity | NPD6798 | Discontinued |
0.7133 | Intermediate Similarity | NPD6410 | Clinical (unspecified phase) |
0.7114 | Intermediate Similarity | NPD1652 | Phase 2 |
0.7103 | Intermediate Similarity | NPD230 | Phase 1 |
0.7097 | Intermediate Similarity | NPD6585 | Discontinued |
0.7095 | Intermediate Similarity | NPD1471 | Phase 3 |
0.7093 | Intermediate Similarity | NPD4360 | Phase 2 |
0.7093 | Intermediate Similarity | NPD4363 | Phase 3 |
0.7091 | Intermediate Similarity | NPD7993 | Clinical (unspecified phase) |
0.708 | Intermediate Similarity | NPD1778 | Approved |
0.7073 | Intermediate Similarity | NPD5844 | Phase 1 |
0.7071 | Intermediate Similarity | NPD1876 | Approved |
0.7059 | Intermediate Similarity | NPD4287 | Approved |
0.7052 | Intermediate Similarity | NPD4361 | Phase 2 |
0.7052 | Intermediate Similarity | NPD4362 | Clinical (unspecified phase) |
0.7051 | Intermediate Similarity | NPD5890 | Approved |
0.7051 | Intermediate Similarity | NPD5889 | Approved |
0.7044 | Intermediate Similarity | NPD955 | Approved |
0.7042 | Intermediate Similarity | NPD2861 | Phase 2 |
0.7027 | Intermediate Similarity | NPD5406 | Approved |
0.7027 | Intermediate Similarity | NPD5405 | Approved |
0.7027 | Intermediate Similarity | NPD5408 | Approved |
0.7027 | Intermediate Similarity | NPD5404 | Approved |
0.702 | Intermediate Similarity | NPD3295 | Clinical (unspecified phase) |
0.7013 | Intermediate Similarity | NPD6980 | Clinical (unspecified phase) |
0.7012 | Intermediate Similarity | NPD3751 | Discontinued |
0.7011 | Intermediate Similarity | NPD8090 | Clinical (unspecified phase) |
0.7008 | Intermediate Similarity | NPD846 | Approved |
0.7008 | Intermediate Similarity | NPD940 | Approved |
0.7 | Intermediate Similarity | NPD9265 | Clinical (unspecified phase) |
0.7 | Intermediate Similarity | NPD290 | Approved |
0.6986 | Remote Similarity | NPD1184 | Approved |
0.6978 | Remote Similarity | NPD1091 | Approved |
0.6974 | Remote Similarity | NPD7440 | Discontinued |
0.6966 | Remote Similarity | NPD520 | Approved |
0.6966 | Remote Similarity | NPD6233 | Phase 2 |
0.6964 | Remote Similarity | NPD8312 | Approved |
0.6964 | Remote Similarity | NPD8313 | Approved |
0.6963 | Remote Similarity | NPD6671 | Approved |
0.6954 | Remote Similarity | NPD7003 | Approved |
0.6943 | Remote Similarity | NPD2366 | Approved |
0.6937 | Remote Similarity | NPD6971 | Discontinued |
0.6929 | Remote Similarity | NPD1242 | Phase 1 |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.